Utility of High-Sensitivity Modified Glasgow Prognostic Score in Cancer Prognosis: A Systemic Review and Meta-Analysis

被引：19

作者：

Wu, Tsung-Hsien ^{[1
,2
]}

Tsai, Yao-Te ^{[3
,4
]}

Chen, Kuan-Yin ^{[5
]}

Yap, Wing-Keen ^{[6
]}

Luan, Chih-Wei ^{[4
,7
,8
,9
]}

机构：

[1] Natl Taiwan Univ, Inst Hlth Policy & Management, Taipei 100, Taiwan

[2] Legal Affair Dept, New Taipei City Dept, Taipei, Taiwan

[3] Chang Gung Univ, Coll Med, Taoyuan 333, Taiwan

[4] Chang Gung Mem Hosp, Dept Otorhinolaryngol Head & Neck Surg, Chiayi 613, Taiwan

[5] Natl Yang Ming Univ, Sch Dent, Taipei 11221, Taiwan

[6] Chang Gung Mem Hosp, Proton & Radiat Therapy Ctr, Linkou Med Ctr, Dept Radiat Oncol, Taoyuan, Taiwan

[7] Minist Hlth & Welf Home, LO Sheng Hosp, Dept Otorhinolaryngol Head & Neck Surg, Taipei 242, Taiwan

[8] Lunghwa Univ Sci & Technol, Gen Educ Ctr, Taoyuan 33306, Taiwan

[9] Chang Gung Univ, Grad Inst Clin Med Sci, Coll Med, Taoyuan 333, Taiwan

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2023年 / 24卷 / 02期

关键词：

high-sensitivity modified Glasgow Prognostic Score; cancer; survival outcome; meta-analysis; C-REACTIVE PROTEIN; INFLAMMATION; SURVIVAL; RATIO; LYMPHOCYTE; SUPERIOR;

D O I：

10.3390/ijms24021318

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The suitability of the high-sensitivity modified Glasgow Prognostic Score (HS-mGPS) in cancer patients remains unknown. We performed a systematic database search from 1 January 2010 to 30 September 2022, in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Selected studies reported the HS-mGPS and survival outcomes in cancer patients. The association between the HS-mGPS and survival outcomes was evaluated using a random-effects model and expressed as pooled hazard ratios (HRs) with 95% CIs. This meta-analysis evaluated 17 studies with a total of 5828 cancer patients. A higher HS-mGPS was found to be associated with an adverse OS (HR = 2.17; 95% CI: 1.80-2.60), DSS (HR = 3.81; 95% CI: 2.03-7.17), and DFS (HR = 1.96; 95% CI: 1.48-2.58; all p <= 0.001). The prognostic value of the HS-mGPS for the OS trended in a consistent direction after subgrouping and sensitivity analysis. In conclusion, the HS-mGPS serves as a valid prognostic biomarker for cancer patients, with a high HS-mGPS associated with adverse survival outcomes.

引用

页数：13

共 46 条

[1] Prognostic Value of High-Sensitivity Modified Glasgow Prognostic Score in Castration-Resistant Prostate Cancer Patients Who Received Docetaxel [J].